Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2025-12-25 @ 10:25 PM
Study NCT ID:
NCT05631158
Status:
UNKNOWN
Last Update Posted:
2022-11-30
First Post:
2022-11-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neuromelanin MRI: A Progression Marker in Early PD
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}, {'id': 'D018450', 'term': 'Disease Progression'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D006403', 'term': 'Hematologic Tests'}, {'id': 'D010808', 'term': 'Physical Examination'}], 'ancestors': [{'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 135}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-11-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-03', 'completionDateStruct': {'date': '2024-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-11-18', 'studyFirstSubmitDate': '2022-11-18', 'studyFirstSubmitQcDate': '2022-11-18', 'lastUpdatePostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Neuromelanin signal in PD', 'timeFrame': '6 months', 'description': 'The primary outcome measure of this study is the neuromelanin-related signal on dedicated 3T MRI.'}], 'secondaryOutcomes': [{'measure': 'Depigmentation rates', 'timeFrame': '2 years', 'description': "* differences in depigmentation rates between Parkinson's and controls in extended retrospective cohorts (discovery)\n* to assess whether earlier depigmentation rates can predict longer term clinical change based on commonly used outcome markers in clinical trials"}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Parkinson Disease', 'Progression, Disease']}, 'descriptionModule': {'briefSummary': "Prospective observational study to qualify NM-MRI as progression marker in early Parkinson's.", 'detailedDescription': "Parkinson's is the second most common neurodegenerative disorder with progressive, disabling motor and non- motor symptoms for which effective symptomatic, but non disease-modifying treatment is available. Neuromelanin- containing neurons in the substantia nigra undergo neurodegeneration during Parkinson's disease. There is considerable heterogeneity in the progression of cell loss and clinical symptoms with major research interest in identifying prognostic subtypes.\n\nA non-invasive biomarker that can track the loss of the neuromelanin-containing neurons would be highly desirable to (i) study subtype-specific trajectories of SN depigmentation, (ii) track disease progression in early Parkinson's to assist in stratifying groups and outcome assessment in clinical intervention trials, and (iii) enable patients and their families to better manage their condition including informed forward planning. Neuromelanin MRI (NM-MRI) is a new approach sensitive to the neuromelanin-iron complex, with proven association with the tissue changes of the number of the neuromelanin-containing neurons. Its diagnostic value was established in several studies case-control, but there is a lack of standardisation, multi-centre studies and prospective diagnostic trials. To date only a small, single arm retrospective study reported serial NM loss in Parkinson's.\n\nBuilding on our previous work, the proposed research entails the development of an early progression biomarker for Parkinson's disease that is pathologically relevant, non-invasive, and uses MRI which is a widely available imaging method for detection. The experimental approach combines advanced computational imaging, retrospective use and extension of existing cohorts with a new dedicated prospective serial study using NM-MRI in uncertain parkinsonism, de novo and early Parkinson and healthy controls using latest MRI technology."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'All potential participants need to have to capacity to give consent prior to study enrolment. Study participation is not possible if the participant is unable to give consent or does not have the capacity to consent.', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n-Inclusion criteria for patients:\n\n* For Parkinson's patients and early-onset Parkinson's:\n\n 1. Diagnosis of Parkinson's disease, based on UK Brain Bank criteria and made within the preceding 3 years ('recent onset cases'); or\n 2. diagnosed at under 50 years ('under 50 years cases')\n* For clinical symptoms suspicious for a diagnosis of PD but clinical uncertainty with regard to a definite diagnosis:\n\n 1. clinical symptoms not meeting all of the required UK Brain Bank diagnostic criteria for the diagnosis of PD; or\n 2. clinical features not typically associated with PD and therefore raising the possibility of a different type disorder/movement disorder referred for a DaTSCAN as part of the National Health Service (NHS) clinical diagnostic work-up to investigate a suspicion for a parkinsonian movement disorder-type disease, or referred for a research DaTSCAN as part of existing N3iPD and PaMIR studies for the diagnostic work-up to investigate a suspicion for a parkinsonian movement disorder-type disease.\n* Age ≥18 to \\<90years\n* Being able and willing to provide informed consent\n\nInclusion criteria for healthy controls:\n\n* Age ≥18 to \\<90years\n* Being able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Exclusion criteria for patients:\n\n 1. The patient has severe comorbid illness that would prevent full study participation\n 2. The patient has features indicating another type of degenerative parkinsonism, e.g. progressive supranuclear palsy\n 3. Drug-induced parkinsonism (Drug-unmasked PD is allowed)\n 4. Symmetrical lower body parkinsonism attributable to significant cortical and/or subcortical cerebrovascular disease (patients with 'incidental' small vessel disease on brain imaging are allowed).\n 5. Negative or normal functional imaging of the presynaptic dopamine system\n 6. The presence of UK Brain Bank exclusion criteria will be recorded at baseline, allowing for the presence of 1 or 2 exclusion criteria (e.g. dopamine antagonist Drug used; more than one affected relative) (if justified e.g. by abnormal SPECT).\n 7. Any contraindication to Magnetic Resonance (MR) scanning.\n 8. Any major neurological (other than PD), psychiatric or cardiovascular disease or history of brain injury.\n 9. Medical illness or medication that may affect brain morphometry or function.\n 10. Patient who is pregnant and/or breastfeeding.\n\nExclusion criteria for healthy controls:\n\n1. Subject has severe comorbid illness that would prevent study participation\n2. Subject already has a diagnosis of Parkinson's disease\n3. Any contraindication to Magnetic Resonance (MR) scanning\n4. Subject who is pregnant and/or breastfeeding."}, 'identificationModule': {'nctId': 'NCT05631158', 'acronym': 'InsIghtPD', 'briefTitle': 'Neuromelanin MRI: A Progression Marker in Early PD', 'organization': {'class': 'OTHER', 'fullName': 'University of Nottingham'}, 'officialTitle': "In Vivo Serial Neuromelanin MRI to Assess Depigmentation Rates in the Substantia Nigra of Early Parkinson's Disease", 'orgStudyIdInfo': {'id': '281685'}}, 'armsInterventionsModule': {'armGroups': [{'label': "Early Parkinson's disease", 'description': 'All the participants will undergo five clinical examination, four MRI scans and one fasting blood test in total in this serial study.', 'interventionNames': ['Diagnostic Test: MRI']}, {'label': 'Healthy Controls', 'description': "This cohort will undergo the same procedure of the patient's group.", 'interventionNames': ['Diagnostic Test: MRI']}], 'interventions': [{'name': 'MRI', 'type': 'DIAGNOSTIC_TEST', 'otherNames': ['Blood test', 'Physical examination'], 'description': 'The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.\n\nAll the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.\n\nFor future proving the value of our study, we will also collect and store blood samples at the initial visit.', 'armGroupLabels': ["Early Parkinson's disease", 'Healthy Controls']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Nottingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Yue (Lily) Xing, PhD', 'role': 'CONTACT', 'email': 'Yue.Xing@nottingham.ac.uk'}], 'facility': 'University of Nottingham', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}], 'centralContacts': [{'name': 'Yue (Lily) Xing, PhD', 'role': 'CONTACT', 'email': 'Yue.Xing@nottingham.ac.uk', 'phone': '44-01158232877'}, {'name': 'Dorothee Auer, MD PhD', 'role': 'CONTACT', 'email': 'Dorothee.Auer@nottingham.ac.uk'}]}, 'ipdSharingStatementModule': {'infoTypes': ['ANALYTIC_CODE'], 'timeFrame': 'within 5 years', 'ipdSharing': 'YES', 'description': 'A new high-quality neuromelanin MRI database with linked whole brain multimodal MRI, clinical findings and stored blood samples. We intend to quality control and curate the imaging and clinical data for the generation of a data repository, and have included cost for data storage, but ultimately intend to integrate this into the Critical Pathway Initiative. Where possible. We also aim to release imaging-derived parameters to make the data usable for non-imaging communities.', 'accessCriteria': 'Open access'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Nottingham', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}